To include your compound in the COVID-19 Resource Center, submit it here.

MAbs could alter PDLI core program

Protein Design Labs Inc. acquired from Sandoz Pharma Ltd. and Sandoz Pharmaceuticals Corp. two human antiviral monoclonal antibodies that will become its lead clinical candidates, as well as the technology to produce them. That technology will be compared to PDLI's own Smart antibody technology and could supplant it

Read the full 489 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE